CStone Pharmaceuticals, a leading biopharmaceutical company, and Pfizer Inc. announced that the National Medical Products Administration (NMPA) of China has approved sugemalimab (Cejemly) for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. Together with the previous approval of the treatment for first-line stage IV NSCLC patients, sugemalimab is now the only anti- PD-1/PD-L1 monoclonal antibody for both stage III and stage IV NSCLC patients.
Dr. Frank Jiang, CEO of CStone, said,
